Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Synucleozid is a potent the SNCA mRNA inhibitor that encodes α-synuclein protein (IC50=1.5 μM), has the potential for the investigation of Parkinson’s disease.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | Synucleozid is a potent the SNCA mRNA inhibitor that encodes α-synuclein protein (IC50=1.5 μM), has the potential for the investigation of Parkinson’s disease. |
ターゲット&IC50 | SNCA IRE RNA:1.5 μM |
In vitro | Synucleozid (0.25-1 μM; 24 hours) eliminates α-synuclein preformed fibrils induced cytotoxicity, fibrils act as seeds and recruit endogenous α-synuclein aggregation.Synucleozid (0-1 μM; 24 hours) binds to the A bulge near the base of the IRE hairpin, reduced levels of α-synuclein in a dose-dependent manner(IC50 : 500 nM), and inhibits α-synuclein protein expression in SH-SY5Y neuroblastoma cells.Synucleozid (100 nM-100 μM; 24 hours) binds to 2-AP-labeled and native IRE RNA with similar affinities. It decreases 2-AP emission(EC50?value of 2.7 μM), recovery of 2-AP emissions is observed as a function of unlabeled?SNCA?IRE RNA (RNA-0) concentration, affording a competitive?Kd?of 1.5 μM.Synucleozid (0.25-1 μM; 24 hours) decreases α-synuclein and other proteins that have IREs in their mRNA's UTR including APP, PrP, Ferritin and TfR as a dose-dependent mannner. All panels is completed in SH-SY5Y cells, except for PrP protein which is assessed in Neuro-2A cells. |
別名 | NSC 377363 |
分子量 | 368.43 |
分子式 | C22H20N6 |
CAS No. | 502139-01-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Synucleozid 502139-01-7 Others NSC-377363 NSC377363 NSC 377363 Inhibitor inhibitor inhibit